Literature DB >> 21683731

Disparate effects of pramipexole on locomotor activity and sensorimotor gating in Sprague-Dawley rats.

Wei-li Chang1, Michelle R Breier, Alex Yang, Neal R Swerdlow.   

Abstract

Prepulse inhibition (PPI) of acoustic startle and locomotor activity are both widely studied in the preclinical development of dopaminergic agents, including those acting at D3 dopamine receptors. In mice, the dopamine D3 receptor-preferential agonist pramipexole (PPX) alters locomotor activity in a biphasic manner at doses that have no effect on PPI. The present study examined the time-course of PPX effects on locomotion and PPI in rats. In adult male Sprague-Dawley rats, PPX (0, 0.1, 0.3, 1.0mg/kg) was injected prior to measurement of locomotor activity for 90 min in photobeam chambers. Based on disparate early vs. late effects of PPX on locomotion, the effects of PPX (0 vs. 0.3mg/kg) on PPI were tested 20 and 80 min after injection. All doses of PPX decreased locomotor activity for 30 min compared to vehicle, and the higher doses stimulated hyperlocomotion later in the session; the late hyperlocomotion, but not the early hypolocomotion, was blocked by the D2-selective antagonist, L741626 (1.0mg/kg sc). In contrast to its locomotor effects, PPX caused a similar reduction in PPI at 20 and 80 min after administration. These findings suggest both a temporal and pharmacological dissociation between PPX effects on locomotor activity and PPI; these two behavioral measures contribute non-redundant information to the investigation of D3-related behavioral pharmacology.
Copyright © 2011. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21683731      PMCID: PMC5946323          DOI: 10.1016/j.pbb.2011.06.002

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  37 in total

1.  The effects of the dopamine D2 agonist sumanirole on prepulse inhibition in rats.

Authors:  Martin Weber; Wei-Li Chang; Michelle R Breier; Alex Yang; Mark J Millan; Neal R Swerdlow
Journal:  Eur Neuropsychopharmacol       Date:  2010-03-25       Impact factor: 4.600

2.  Effects of selective dopamine D1-like and D2-like agonists on prepulse inhibition of startle in inbred C3H/HeJ, SPRET/EiJ, and CAST/EiJ mice.

Authors:  Rebecca J Ralph; S Barak Caine
Journal:  Psychopharmacology (Berl)       Date:  2006-09-22       Impact factor: 4.530

Review 3.  The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders.

Authors:  P Sokoloff; J Diaz; B Le Foll; O Guillin; L Leriche; E Bezard; C Gross
Journal:  CNS Neurol Disord Drug Targets       Date:  2006-02       Impact factor: 4.388

4.  Effects of antipsychotics and selective D3 antagonists on PPI deficits induced by PD 128907 and apomorphine.

Authors:  Min Zhang; Michael E Ballard; Liliane V Unger; Andreas Haupt; Gerhard Gross; Michael W Decker; Karla U Drescher; Lynne E Rueter
Journal:  Behav Brain Res       Date:  2007-05-01       Impact factor: 3.332

Review 5.  Realistic expectations of prepulse inhibition in translational models for schizophrenia research.

Authors:  Neal R Swerdlow; Martin Weber; Ying Qu; Gregory A Light; David L Braff
Journal:  Psychopharmacology (Berl)       Date:  2008-06-21       Impact factor: 4.530

6.  Locomotor inhibition by the D3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release.

Authors:  K Svensson; A Carlsson; N Waters
Journal:  J Neural Transm Gen Sect       Date:  1994

7.  Behavioral and biochemical effects of the dopamine D3 receptor-selective ligand, 7-OH-DPAT, in the normal and the reserpine-treated rat.

Authors:  S Ahlenius; P Salmi
Journal:  Eur J Pharmacol       Date:  1994-08-01       Impact factor: 4.432

8.  Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine.

Authors:  M Weber; M Breier; D Ko; N Thangaraj; D E Marzan; N R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2008-12-09       Impact factor: 4.530

9.  A novel rat strain with enhanced sensitivity to the effects of dopamine agonists on startle gating.

Authors:  Neal R Swerdlow; Michelle Breier; Adrienne B Mora; David Ko; Jody M Shoemaker
Journal:  Pharmacol Biochem Behav       Date:  2007-09-04       Impact factor: 3.533

10.  Apomorphine-induced disruption of prepulse inhibition that can be normalised by systemic haloperidol is insensitive to clozapine pretreatment.

Authors:  H Russig; W Spooren; S Durkin; J Feldon; B K Yee
Journal:  Psychopharmacology (Berl)       Date:  2004-02-25       Impact factor: 4.530

View more
  9 in total

1.  Effects of pramipexole on the acquisition of responding with opioid-conditioned reinforcement in the rat.

Authors:  Jeremiah W Bertz; Jianyong Chen; James H Woods
Journal:  Psychopharmacology (Berl)       Date:  2014-07-03       Impact factor: 4.530

2.  Pramipexole-induced disruption of behavioral processes fundamental to intertemporal choice.

Authors:  Patrick S Johnson; Jeffrey S Stein; Rochelle R Smits; Gregory J Madden
Journal:  J Exp Anal Behav       Date:  2013-02-22       Impact factor: 2.468

3.  MitoPark mice, an animal model of Parkinson's disease, show enhanced prepulse inhibition of acoustic startle and no loss of gating in response to the adenosine A(2A) antagonist SCH 412348.

Authors:  Steven M Grauer; Robert Hodgson; Lynn A Hyde
Journal:  Psychopharmacology (Berl)       Date:  2013-10-23       Impact factor: 4.530

4.  Stereochemical and neuroanatomical selectivity of pramipexole effects on sensorimotor gating in rats.

Authors:  Wei-Li Chang; Martin Weber; Michelle R Breier; Richard L Saint Marie; Samantha R Hines; Neal R Swerdlow
Journal:  Brain Res       Date:  2011-12-13       Impact factor: 3.252

5.  Effects of the 5HT2C antagonist SB242084 on the pramipexole-induced potentiation of water contrafreeloading, a putative animal model of compulsive behavior.

Authors:  Chiara Schepisi; Lorenza De Carolis; Paolo Nencini
Journal:  Psychopharmacology (Berl)       Date:  2012-12-16       Impact factor: 4.530

6.  Inhibition of 50-kHz ultrasonic vocalizations by dopamine receptor subtype-selective agonists and antagonists in adult rats.

Authors:  Tina Scardochio; Paul B S Clarke
Journal:  Psychopharmacology (Berl)       Date:  2012-11-29       Impact factor: 4.530

Review 7.  Dopamine D3 and 5-HT1B receptor dysregulation as a result of psychostimulant intake and forced abstinence: Implications for medications development.

Authors:  Janet L Neisewander; Timothy H C Cheung; Nathan S Pentkowski
Journal:  Neuropharmacology       Date:  2013-08-23       Impact factor: 5.250

8.  The adverse effects of pramipexole on probability discounting are not reversed by acute D2 or D3 receptor antagonism.

Authors:  Marco Orrù; Hunter J Strathman; Gabriele Floris; Simona Scheggi; Beth Levant; Marco Bortolato
Journal:  Eur Neuropsychopharmacol       Date:  2020-01-24       Impact factor: 5.415

9.  Chronic pramipexole treatment increases tolerance for sucrose in normal and ventral tegmental lesioned rats.

Authors:  David Dardou; Carine Chassain; Franck Durif
Journal:  Front Neurosci       Date:  2015-01-06       Impact factor: 4.677

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.